Literature DB >> 14630888

Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.

Shirin Sanal1, Wilbert S Aronow.   

Abstract

BACKGROUND: There is a marked underutilization of antiplatelet drugs, beta blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and lipid-lowering drugs, and an overutilization of calcium channel blockers in elderly patients with coronary artery disease (CAD).
METHODS: An ongoing educational program is being given by Dr. Wilbert Aronow on the appropriate utilization of cardiovascular drugs in patients with CAD during hospitalization and at hospital discharge. In a prospective study, charts of 200 unselected patients hospitalized for CAD at least 6 months after the onset of the educational program were analyzed by a medical resident to investigate the appropriate utilization of cardiovascular drugs. The 200 patients included 115 men and 85 women, mean age 70 years, with documented CAD. Of the 200 patients, 127 (64%) had the diagnosis of prior CAD. The use of cardiovascular medications in these 127 patients prior to hospitalization served as a control group.
RESULTS: After the educational program, aspirin, clopidogrel, or warfarin was given to 93% of patients compared with 67% in the control group; beta blockers were given to 81% of patients compared with 56% in the control group; ACE inhibitors or ARBs were given to 70% of patients compared with 42% in the control group. Lipid-lowering drugs if dyslipidemia were given to 88% of patients compared with 52% in the control group; calcium channel blockers were given to 18% of patients compared with 24% in the control group.
CONCLUSIONS: In patients with CAD, the educational program increased the use of antiplatelet drugs by 26%, beta blockers by 25%, ACE inhibitors or ARBs by 28%, and lipid-lowering drugs by 36%, and decreased the use of calcium channel blockers by 6%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630888     DOI: 10.1093/gerona/58.11.m1046

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  5 in total

Review 1.  Lipids and the elderly.

Authors:  Wilbert S Aronow
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

Review 2.  Managing hyperlipidaemia in the elderly: special considerations for a population at high risk.

Authors:  Wilbert S Aronow
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Drug treatment of peripheral arterial disease in the elderly.

Authors:  Wilbert S Aronow
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Peripheral arterial disease of the lower extremities.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

5.  Lipid-lowering therapy in older persons.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2015-01-08       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.